IRCT20200407046981N31尚未招募未知
Comparative bioequivalence study of the Domperidone suspension 1 mg/ml (200 mL) produced by Omid Behboud pharmaceutical Co versus Motilium® (Janssen company)
Omid Behboud Pharmaceutical Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Domperidone or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Domperidone suspension 1 mg/ml in comparison with Domperidone brand suspension (Motilium®).IRCT20200407046981N35ona Darou Pars Pharmaceutical Company24
已完成
不适用
Bioequivalence study of Domperidone 10 mg F.C. Tablet in 24 healthy male under fasting conditionsIRCT20180620040164N12ACtover Pharmaceutical Co.26
尚未招募
不适用
Study of absorption and elimination rate of Dapagliflozin 10-mg tablets in comparison with Dapagliflozin brand tablets (Farxiga®).Bioequivalence study.IRCT20200407046981N45Modava pharmaceutical company24
已完成
不适用
Comparative bioequivalence study of the Dapagliflozin 10-mg tablets manufactured by Noavaran Daroui Kimia CompanyIRCT20130313012810N5KIMIA Noavaran Daroui24
尚未招募
不适用
Study of absorption and elimination rate of Pirfenidone 200-mg Tablets in comparison with Pirfenidone brand Tablets (Pirfenex®).Bioequivalence study.IRCT20200407046981N30Modava pharmaceutical company24